Premium
The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A.
Author(s) -
Ferner RE,
Kamali F,
Rawlins MD
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb03869.x
Subject(s) - sulindac , enalapril , substance p , neurokinin a , pharmacology , neurokinin b , medicine , renin–angiotensin system , endocrinology , angiotensin converting enzyme , neuropeptide , receptor , nonsteroidal , blood pressure
The effects of pretreatment with enalapril, and sulindac, on the weal response to intradermal injections of substance P and neurokinin A were assessed in a randomised, double‐blind, placebo‐controlled study. Weal responses to both substance P and neurokinin A depended significantly on dose. Neither enalapril nor sulindac, nor the combination of these agents influenced the responses to either tachykinin. These results do not suggest any role for substance P or neurokinin A in the clinical effects of angiotensin converting enzyme inhibitors.